81092-89-9

Upstream product

• 88463-18-7 (S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropionamide 
• 76-05-1 trifluoroacetic acid 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 67729-36-6 Boc-Phe-O-COO-isoBu 

Downstream Products

• 81092-90-2 benzyloxycarbonyl-α-tert-butyl-L-aspartyl-β-L-phenylalanine amide 
• 73537-62-9 N^α-tert-Butyloxycarbonyl-β-O-tert-butyl-L-aspartyl-L-phenylalanine amide 
• 33900-05-9 tert-butyl (S)-N-{2-[(2-amino-1-benzyl-2-oxoethyl)amino]-2-oxoethyl}carbamate 
• 27220-69-5 Boc-Ala-Phe-NH₂ 
• 33900-27-5 Boc-Trp-Phe-NH₂ 
• 66851-71-6 L-Aspartyl-L-phenylalanine amide trifluoroacetate 

Relevant academic research and scientific papers

Structural studies of [2′,6′-dimethyl-L-tyrosine1]endomorphin-2 analogues: Enhanced activity and cis orientation of the Dmt-Pro amide bond

Analogues of endomorphin-2 (EM-2: Tyr-Pro-Phe-Phe-NH2) (1) were designed to examine the importance of each residue on μ-opioid receptor interaction. Replacement of Tyr1 by 2′,6′-dimethyl-L-tyrosine (Dmt) (9-12) exerted profound effects: [Dmt1]EM-2 (9) elevated μ-opioid affinity 4.6-fold (Kiμ=0.15 nM) yet selectivity fell 330-fold as δ-affinity rose (Kiδ=28.2 nM). This simultaneous increased μ- and δ-receptor bioactivities resulted in dual agonism (IC50=0.07 and 1.87 nM, respectively). While substitution of Phe4 by a phenethyl group (4) decreased μ affinity (Kiμ=13.3 nM), the same derivative containing Dmt (12) was comparable to EM-2 but also acquired weak δ antagonism (pA2=7.05). 1H NMR spectroscopy revealed a trans configuration (1:2 to 1:3, cis/trans) in the Tyr-Pro amide bond, but a cis configuration (5:3 to 13:7, cis/trans) with Dmt-Pro analogues.

Synthesis, anti-inflammatory and antimicrobial activities of new 1,2,4-oxadiazoles peptidomimetics

A new series of 1,2,4-oxadizoles 6a-g have been synthesised in good yields using the peptide synthesis strategy. The prepared compounds were tested for anti-inflammatory and antimicrobial activities. The anti-inflammatory activities were determined in the

Design of plasma kallikrein inhibitors: Functional and structural requirements of plasma kallikrein inhibitors

The synthetic plasma kallikrein (PK) inhibitor trans-4- aminomethylcyclohexanecarbonylphenylalanine-4-carboxymethylanilide (PKSI- 527) consists of three parts. Each part was replaced by analogues in an attempt to improve the potency and the selectivity of PKSI-527. Among the peptides examined, trans-4-aminomethyl-cyclohexanecarbonylphenylalanine-4- carboxyanilide (peptide 16) inhibited PK with a high selectivity and an IC50 value of 2.7 μM, being as potent as PKSI-527.